Our Research

FirstString Research is a clinical stage biopharmaceutical company developing dermatologic, ophthalmic, organ preservation, and pulmonary therapeutics utilizing our proprietary aCT technology platform. We have developed a product portfolio with a significant addressable market in numerous indications with unmet clinical need. We are focused on developing therapeutic products that address the underlying pathophysiology of inflammation and injury based medical conditions, thereby providing physicians new treatment options.

Our lead dermatological product Granexin® gel, is in late-stage studies for the treatment of cutaneous radiation injury, cutaneous scarring, and thermal burns. FirstString’s pipeline also includes formulations targeting corneal injury, acute/chronic lung injury, and organ preservation.